Problems with the PVA system are expected to be discussed during this year's parliamentary audit of the National Assembly's Health and Welfare Committee. The domestic pharmaceutical community criticized that it is too harsh for the government to unilaterally decide on a drug price cut without acknowledging the innovation of new domestic drugs in the process of operating PVA. Accordingly, the National Assembly's welfare committee members agreed on this.

On the 28th, the National Assembly's Health and Welfare Committee members plan to inquire about the current PVA system operation status, problems claimed by the pharmaceutical industry, and directions for improvement to government agencies such as the MOH